West Pharmaceutical (WST) CEO Michel Lagarde Receives RSU Awards

What Happened

Michel Lagarde, President and CEO of West Pharmaceutical Services (WST), was granted six derivative awards totaling 51,798 restricted stock units (RSUs) on September 8, 2026. The filing lists six grants of 13,879; 11,081; 12,088; 6,200; 4,950; and 3,600 RSUs. Each award is reported at $0 per unit in the Form 4 because these are contingent equity awards (not open-market purchases).

This is an award/compensation event (transaction code A) rather than a buy or sell — not an immediate market transaction and not a realized cash value until the RSUs vest and convert to shares.

Key Details

• Transaction date: September 8, 2026. Form 4 filed September 10, 2026 (appears timely).
• Awards: six grants totaling 51,798 RSUs (13,879; 11,081; 12,088; 6,200; 4,950; 3,600). Reported price/value: $0 (derivative awards).
• Vesting notes from the filing: some awards vest in four equal annual installments beginning September 8, 2027 (F1); others cliff-vest on September 8, 2031 (F2). Each RSU represents the contingent right to one share of WST common stock (F3).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Filing timeliness: filed two days after the grants; appears to meet the typical Form 4 reporting window.

Context

Restricted stock units are deferred-compensation awards that convert to company shares only if and when they vest; until vesting they are contingent and typically reported at $0 on Form 4. Awards to executives are common for retention and alignment with shareholders; this filing documents grants but does not indicate any immediate sale or purchase of stock by the insider.